



## INDEPENDENT AUDITORS' REPORT

### To the Board of Directors of Hamps Bio Limited

#### Opinion

We have audited the condensed standalone interim financial statements of Hamps Bio Limited ("the Company"), which comprises the condensed standalone interim balance sheet as at 31 October 2024, the condensed standalone interim statement of profit and loss for the quarter and year-to-date period then ended, the condensed standalone interim statement of cash flows for the year-to-date period then ended, and notes to the condensed standalone interim financial statements, including a summary of the significant accounting policies ("the condensed standalone interim financial statements") and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid condensed standalone interim financial statements give a true and fair view in conformity with Accounting standard 25 and other accounting principles generally accepted in India, of the state of affairs of the Company as at 31 October, 2024, profit and other comprehensive income for the quarter and year-to-date period then ended, changes in equity and its cash flows for the year-to-date-period ended on that date.

#### Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Condensed Standalone Interim Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the condensed standalone interim financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### Management's Responsibilities for the Condensed Standalone Interim Financial Statements

The Company's management and the Board of Directors are responsible for the preparation of these condensed standalone interim financial statements that give a true and fair view of the state of affairs, profit/loss and other comprehensive income, changes in equity and cash flows of the Company in accordance with **AS 25** prescribed under section 133 of the Act and other accounting principles generally accepted in India. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring accuracy and



completeness of the accounting records, relevant to the preparation and presentation of the condensed standalone interim financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the condensed standalone interim financial statements, the management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process

#### **Auditor's Responsibilities for the Audit of the Condensed Standalone Interim Financial Statements**

Our objectives are to obtain reasonable assurance about whether the condensed standalone interim financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these condensed standalone interim financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the condensed standalone interim financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the condensed standalone interim financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report.



However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the condensed standalone interim financial statements, including the disclosures, and whether the condensed standalone interim financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For MGVS & Associates  
Chartered Accountants,  
FRN: 140555W



CA MUBASSIR GODIL  
(PARTNER)

M. No. 164503

UDIN: 24164503BKDKST7871

Date: 02/12/2024

Place: ANKLESHWAR

**HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)**  
(CIN: U24233GJ2007PLC049692)  
(Address: 2900/112, Near Atul Limited, G.I.D.C., Ankleshwar, Dist. Bharuch, Gujarat - 393002)  
**Balance Sheet as at 31 October 2024**

(Rs In lacs)

Particulars	Note	31 October 2024	31 March 2024
<b>I. EQUITY AND LIABILITIES</b>			
<b>(1) Shareholders' funds:</b>			
(a) Share Capital	1	313.60	196.00
(b) Reserves and Surplus	2	54.19	138.44
<b>Total</b>		<b>367.79</b>	<b>334.44</b>
<b>(2) Non-current liabilities</b>			
(a) Long-term Borrowings	3	47.32	29.55
(b) Other Long-term Liabilities	4	9.70	7.33
<b>Total</b>		<b>57.02</b>	<b>36.88</b>
<b>(3) Current liabilities</b>			
(a) Short-term Borrowings	5	91.00	74.97
(b) Trade Payables	6		
- Due to Micro and Small Enterprises		7.47	19.51
- Due to Others		29.13	8.17
(c) Other Current Liabilities	7	76.09	20.99
(d) Short-term Provisions	8	12.52	16.83
<b>Total</b>		<b>216.21</b>	<b>140.47</b>
<b>Total Equity and Liabilities</b>		<b>641.02</b>	<b>511.79</b>
<b>II. ASSETS</b>			
<b>(1) Non-current assets:</b>			
(a) Property, Plant and Equipment and Intangible Assets			
(i) Property, Plant and Equipment	9	309.86	252.37
(b) Non-current Investments	10	3.06	0.11
(c) Deferred Tax Assets (net)	11	6.72	6.30
(d) Other Non-current Assets	12	23.12	9.31
<b>Total</b>		<b>342.76</b>	<b>268.09</b>
<b>(2) Current assets:</b>			
(a) Inventories	13	165.26	122.82
(b) Trade Receivables	14	99.97	98.93
(c) Cash and cash equivalents	15	10.56	5.84
(d) Short-term Loans and Advances	16	23.26	12.43
(e) Other Current Assets	17	5.21	3.68
<b>Total</b>		<b>298.26</b>	<b>243.70</b>
<b>Total Assets</b>		<b>641.02</b>	<b>511.79</b>

See accompanying notes to the financial statements

As per our report of even date  
For MGVS & Associates  
Chartered Accountants  
Firm's Registration No. 0140355W

CA MUBASSIR M GODIL  
PARTNER  
Membership No. 164503  
UDIN: 2416 4503BKDKST7871  
Place: ANKLESHWAR  
Place: ANKLESHWAR

For and on behalf of the Board of  
HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)

  
SHRENIK SHAH  
MANAGING DIRECTOR  
01052316

  
SHRENIK SHAH  
WHOLE TIME DIRECTOR  
00973690

Place: ANKLESHWAR  
Date: 02 December 2024



**HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)**

(CIN: U24233GJ2007PLC049692)

(Address: 2900/112, Near Atul Limited, G.I.D.C., Ankleshwar, Dist. Bharuch, Gujarat - 393002)

**Statement of Profit and loss for the year ended 31 October 2024**

(Rs in lacs)

Particulars	Note	31 October 2024	31 March 2024
Revenue from Operations	18	426.67	647.53
Other Income	19	9.75	2.60
<b>Total Income</b>		<b>436.42</b>	<b>650.13</b>
<b>Expenses</b>			
Cost of Material Consumed	20	33.55	31.06
Purchases of Stock in Trade	21	121.23	217.10
Change in inventories of work in progress and finished goods	22	(29.47)	(77.81)
Employee Benefit Expenses	23	111.21	158.86
Finance Costs	24	7.75	14.97
Depreciation and Amortization Expenses	25	21.18	40.36
Other Expenses	26	124.79	200.59
<b>Total expenses</b>		<b>390.23</b>	<b>585.13</b>
<b>Profit/(Loss) before Exceptional and Extraordinary Item and Tax</b>		<b>46.18</b>	<b>65.00</b>
Exceptional Item		-	-
<b>Profit/(Loss) before Extraordinary Item and Tax</b>		<b>46.18</b>	<b>65.00</b>
Extraordinary Item		-	-
<b>Profit/(Loss) before Tax</b>		<b>46.18</b>	<b>65.00</b>
<b>Tax Expenses</b>	27		
- Current Tax		12.52	16.58
- Deferred Tax		(0.42)	(1.65)
<b>Profit/(Loss) after Tax</b>		<b>34.08</b>	<b>50.07</b>
<b>Earnings Per Share (Face Value per Share Rs.10 each)</b>			
-Basic (In Rs)	28	1.09	2.55
-Diluted (In Rs)	28	1.09	2.55

See accompanying notes to the financial statements.

As per our report of even date

For MGVS & Associates

Chartered Accountants

Firm's Registration No. 0140555W

For and on behalf of the Board of

HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)

CA MUBASSIR M GODIL  
PARTNER

Membership No. 164503

UDIN: 24164503BKDKST7871

Place: ANKLESHWAR

Date: 02 December 2024

HERRIK SHAH  
MANAGING DIRECTOR  
01052316

SHRENIK SHAH  
WHOLE TIME DIRECTOR  
00973690

Place: ANKLESHWAR

Date: 02 December 2024

**HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)**  
(CIN: U24233GJ2007PLC049692)  
(Address: 2900/112, Near Atul Limited, G.I.D.C., Ankleshwar, Dist. Bharuch, Gujarat - 393002)  
**Cash Flow Statement for the year ended 31 October 2024**

(Rs in lacs)

Particulars	Note		
		31 October 2024	31 March 2024
<b>CASH FLOW FROM OPERATING ACTIVITIES</b>			
Net Profit after tax		34.08	50.06
Profit/(loss) from Discontinuing Operation (after tax)		-	-
Depreciation and Amortisation Expense		21.18	40.36
Provision for tax		12.10	14.93
Effect of Exchange Rate Change		-	-
Loss/(Gain) on Sale / Discard of Assets (Net)		-	-
Bad debt, provision for doubtful debts		-	-
Net Loss/(Gain) on Sale of Investments		-	-
Other Adjustments		(0.74)	(4.59)
Dividend Income		-	-
Interest Income		-	(0.47)
Finance Costs		7.75	14.97
Operating Profit before working capital changes		74.37	115.25
<b>Adjustment for:</b>			
Inventories		(42.44)	(85.10)
Trade Receivables		4.96	(22.97)
Loans and Advances		(10.81)	(12.43)
Other Current Assets		(1.53)	1.98
Other Non current Assets		-	(1.66)
Trade Payables		8.92	(23.08)
Other Current Liabilities		55.10	(9.39)
Long term Liabilities		2.37	-
Short-term Provisions		(4.31)	16.83
Long-term Provisions		-	7.33
Cash (Used in)/Generated from Operations		86.63	(14.22)
Tax paid(Net)		12.10	14.93
Net Cash (Used in)/Generated from Operating Activities		74.53	(29.15)
<b>CASH FLOW FROM INVESTING ACTIVITIES</b>			
Purchase of Property, Plant and Equipment		(78.67)	(36.20)
Sale of Property, Plant and Equipment		-	-
Purchase of Investments Property		-	-
Sale of Investment Property		-	-
Purchase of Equity Instruments		-	-
Proceeds from Sale of Equity Instruments		-	-
Purchase of Mutual Funds		-	-
Proceeds from Sale / Redemption of Mutual Funds		-	0.15
Purchase of Preference Shares		-	-
Proceeds from Sale/Redemption of Preference Shares		-	-
Purchase of Government or trust securities		-	-
Proceeds from Sale/Redemption of Government or trust securities		-	-
Purchase of debentures or bonds		-	-
Proceeds from Sale/Redemption of debentures or bonds		-	-
Purchase of Other Investments		-	-
Sale / Redemption of Other Investments		-	-
Loans and Advances given		-	-
Proceeds from Loans and Advances		-	-
Investment in Term Deposits		(2.95)	-
Maturity of Term Deposits		-	-
Movement in other non current assets		(14.23)	(1.10)
Interest received		-	0.47
Dividend received		-	-
Net Cash (Used in)/Generated from Investing Activities		(95.85)	(36.67)
<b>CASH FLOW FROM FINANCING ACTIVITIES</b>			
Proceeds from Issue of Share Capital		-	151.00
Buyback of Shares		-	-
Proceeds from Long Term Borrowings		17.76	-
Repayment of Long Term Borrowings		-	(12.06)
Proceeds from Short Term Borrowings		16.03	-

Repayment of Short Term Borrowings		-	(57.18)
Minority Interest Movement		-	-
Dividends Paid (Including Dividend Distribution Tax)		-	-
Interest Paid		(7.75)	(14.97)
Net Cash (Used in)/Generated from Financing Activities		20.04	69.78
Net Increase/(Decrease) in Cash and Cash Equivalents		4.72	0.96
Opening Balance of Cash and Cash Equivalents		5.84	4.83
Exchange difference of Foreign Currency Cash and Cash equivalents		-	-
Closing Balance of Cash and Cash Equivalents	15	10.56	5.84

Note:

The above Cash Flow Statement has been prepared under the 'indirect Method' as set out in the Accounting Standard 3 (AS-3), "Cash Flow Statements".

See accompanying notes to the financial statements

As per our report of even date  
For MGV & Associates  
Chartered Accountants  
Firm's Registration No. 0140555W

For and on behalf of the Board of

HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)

CA MUBASSIR M GODIL  
PARTNER  
Membership No. 164503  
UDIN: 241645038KDKST7871  
Place: ANKLESHWAR  
Date: 02 December 2024

  
HERRIK SHAH  
MANAGING DIRECTOR  
01052316

  
SHRENIK SHAH  
WHOLE TIME DIRECTOR  
00973690



**HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)**  
(CIN: U24233GJ2007PLC049692)  
Notes forming part of the Financial Statements

1 Share Capital

Particulars	(Rs in lacs)	
	31 October 2024	31 March 2024
<b>Authorised Share Capital</b>		
Equity Shares, Rs. 10 par value, 5000000 (Previous Year -1510000) Equity Shares	500.00	500.00
<b>Issued, Subscribed and Fully Paid up Share Capital</b>		
Equity Shares, Rs. 10 par value 3136000 (Previous Year -1960000) Equity Shares paid up	313.60	196.00
<b>Total</b>	<b>313.60</b>	<b>196.00</b>

(i) Reconciliation of number of shares

Particulars	31 October 2024		31 March 2024	
	No. of shares	(Rs in lacs)	No. of shares	(Rs in lacs)
Opening Balance	1,960,000	196.00	1,500,000	150.00
Issued during the year	1,176,000	117.60	460,000	46.00
Deletion	-	-	-	-
<b>Closing balance</b>	<b>3,136,000</b>	<b>313.60</b>	<b>1,960,000</b>	<b>196.00</b>

(ii) Rights, preferences and restrictions attached to shares

Equity Shares: The Company has one class of equity shares. Each shareholder is eligible for one vote per share held. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting, except in case of interim dividend. In the event of liquidation, the equity shareholders are eligible to receive the remaining assets of the Company after distribution of all preferential amounts, in proportion to their shareholding.

(iii) Details of Shares held by shareholders holding more than 5% of the aggregate shares in the company

Equity Shares Name of Shareholder	31 October 2024		31 March 2024	
	No. of shares	In %	No. of shares	In %
Alka Shah	-	0.00%	277,765	14.17%
Herrick Mountbaton Shah	1,355,384	43.22%	392,047	20.00%
Mountbaton Shah	-	0.00%	366,568	18.70%
Mountbaton Shah HUF	-	0.00%	100,075	5.11%
Pallavi Shah	-	0.00%	222,098	11.33%
Shrenik Shah	1,026,341	32.73%	317,963	16.22%
Herrick Mountbaton Shah HUF	229,454	7.32%	143,409	7.32%

(iv) Shares held by Promoters at the end of the year 31 October 2024

Name of Promoter	Class of Shares	No. of Shares	% of total shares	% Change during the year
Alka Shah	Equity Shares	-	0.00%	-100.00%
Herrick Mountbaton Shah	Equity Shares	1,355,384	43.22%	23.22%
Mountbaton Shah	Equity Shares	-	0.00%	-100.00%
Mountbaton Shah HUF	Equity Shares	-	0.00%	-100.00%
Pallavi Shah	Equity Shares	147,357	4.70%	-6.63%
Shrenik Shah	Equity Shares	1,026,341	32.73%	16.51%
Herrick Mountbaton Shah HUF	Equity Shares	229,454	7.32%	0.00%
Shrenik Shah HUF	Equity Shares	128,120	4.09%	0.00%
Mitali Shah	Equity Shares	32,000	1.02%	0.00%

Shares held by Promoters at the end of the year 31 March 2024

Name of Promoter	Class of Shares	No. of Shares	% of total shares	% Change during the year
Alka Shah	Equity Shares	277,765	14.17%	3.73%
Herrick Mountbaton Shah	Equity Shares	392,047	20.00%	47.73%
Mountbaton Shah	Equity Shares	366,568	18.70%	13.41%
Mountbaton Shah HUF	Equity Shares	100,075	5.11%	11.10%
Pallavi Shah	Equity Shares	222,098	11.33%	31.60%
Shrenik Shah	Equity Shares	317,963	16.22%	20.15%
Herrick Mountbaton Shah HUF	Equity Shares	143,409	7.32%	138.72%
Shrenik Shah HUF	Equity Shares	80,075	4.09%	33.29%
Bhavya Shah	Equity Shares	40,000	2.04%	0.00%
Mitali Shah	Equity Shares	20,000	1.02%	0.00%



2 Reserves and Surplus (Rs in lacs)

Particulars	31 October 2024	31 March 2024
<b>Securities Premium</b>		
Opening Balance	105.00	-
Add: Issue of Shares		105.00
Less: Appropriation	105.00	-
Closing Balance	-	105.00
<b>Statement of Profit and loss</b>		
Balance at the beginning of the year	33.44	(12.03)
Add: Profit/(loss) during the year	34.08	50.06
Less: Appropriation	12.60	
Other Adjustments	0.74	4.59
<b>Balance at the end of the year</b>	<b>54.19</b>	<b>33.44</b>
<b>Total</b>	<b>54.19</b>	<b>138.44</b>

3 Long term borrowings (Rs in lacs)

Particulars	31 October 2024	31 March 2024
Secured Term loans from banks	22.82	29.55
Unsecured Loans and advances from related parties	24.50	-
<b>Total</b>	<b>47.32</b>	<b>29.55</b>

4 Other Long term liabilities (Rs in lacs)

Particulars	31 October 2024	31 March 2024
Others		
-Retirement Benefit Obligation	9.70	7.33
<b>Total</b>	<b>9.70</b>	<b>7.33</b>

5 Short term borrowings (Rs in lacs)

Particulars	31 October 2024	31 March 2024
Current maturities of long-term debt	11.45	15.98
Secured Loans repayable on demand from banks	79.55	58.99
<b>Total</b>	<b>91.00</b>	<b>74.97</b>

6 Trade payables (Rs in lacs)

Particulars	31 October 2024	31 March 2024
Due to Micro and Small Enterprises		
-Due to Micro and Small Enterprises	7.47	19.51
Due to others		
-Due to others	29.13	8.17
<b>Total</b>	<b>36.60</b>	<b>27.68</b>

6.1 Trade Payable ageing schedule as at 31 October 2024 (Rs in lacs)

Particulars	Outstanding for following periods from due date of payment				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
MSME	7.47				7.47
Others	29.13				29.13
Disputed dues- MSME					-
Disputed dues- Others					-
<b>Sub total</b>					<b>36.60</b>
MSME - Undue					-
Others - Undue					-
<b>Total</b>					<b>36.60</b>

## 6.2 Trade Payable ageing schedule as at 31 March 2024

(Rs in lacs)

Particulars	Outstanding for following periods from due date of payment				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
MSME	19.51				19.51
Others	8.17				8.17
Disputed dues- MSME					-
Disputed dues- Others					-
<b>Sub total</b>					<b>27.68</b>
MSME - Undue					-
Others - Undue					-
<b>Total</b>					<b>27.68</b>

## 7 Other current liabilities

(Rs in lacs)

Particulars	31 October 2024	31 March 2024
Statutory dues		
-Statutory dues	1.73	7.92
Other payables		
-Other payables	12.85	12.91
Retirement Benefit Obligation	0.19	0.16
Advance from Customers	17.83	-
Other Liabilities	43.49	-
<b>Total</b>	<b>76.09</b>	<b>20.99</b>

## 8 Short term provisions

(Rs in lacs)

Particulars	31 October 2024	31 March 2024
Provision for income tax		
-Current Year Tax	12.52	16.58
Provision for others		
-Audit Fees Payable	-	0.25
<b>Total</b>	<b>12.52</b>	<b>16.83</b>

**HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)**

(CIN: U24233GJ2007PLC049692)

Notes forming part of the Financial Statements

Property, Plant and Equipment	Gross Block		Depreciation and Amortization		Net Block	
	As on 01-Apr-24	Addition Deduction	As on 31-Oct-24	for the year	As on 31-Oct-24	As on 31-Mar-24
(I) Property, Plant and Equipment						
Land	36.94	1.70	38.64	-	-	36.94
Building	126.20	-	126.20	2.16	52.75	73.45
Factory Building	21.55	8.64	30.19	0.82	7.62	22.57
Office Equipments	22.18	1.22	23.40	1.69	18.06	5.34
Electric installation	23.34	1.00	24.34	1.82	13.99	10.35
Computers	17.47	1.15	18.62	0.95	16.50	2.11
Furniture and Fixtures	23.85	2.96	26.82	2.06	14.03	12.78
Plant and Machinery	153.61	60.99	214.60	8.05	90.62	124.19
Motor Vehicles	39.25	-	39.25	2.99	22.57	16.69
Laboratory Equipments	6.10	-	6.10	0.56	4.09	2.01
<b>Total</b>	<b>470.70</b>	<b>77.67</b>	<b>548.37</b>	<b>21.08</b>	<b>240.23</b>	<b>308.13</b>
<b>Previous Year</b>	<b>435.39</b>	<b>35.51</b>	<b>470.70</b>	<b>40.28</b>	<b>219.15</b>	<b>251.55</b>

(I) Intangible Assets	Gross Block		Depreciation and Amortization		Net Block	
	As on 01-Apr-24	Addition Deduction	As on 31-Oct-24	for the year	As on 31-Oct-24	As on 31-Mar-24
	0.89	1.00	1.89	0.09	0.16	1.73
<b>Total</b>	<b>0.89</b>	<b>1.00</b>	<b>1.89</b>	<b>0.09</b>	<b>0.16</b>	<b>1.73</b>
<b>Previous Year</b>	<b>-</b>	<b>0.89</b>	<b>0.89</b>	<b>0.07</b>	<b>0.07</b>	<b>0.82</b>

**HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)**  
(CIN: U24233GJ2007PLC049692)  
Notes forming part of the Financial Statements

10 Non current investments (Rs in lacs)

Particulars	31 October 2024	31 March 2024
Unquoted Trade Investments in Equity Instruments		
-Birla Power Solutions Ltd (30000 Equity Shares of Rs. 1 each)	0.11	0.11
Other non-current investments		
-Investment in Mutual Funds	-	-
-Fixed Deposits	2.95	-
<b>Total</b>	<b>3.06</b>	<b>0.11</b>

11 Deferred tax assets net (Rs in lacs)

Particulars	31 October 2024	31 March 2024
Opening Balance	6.30	4.64
Unabsorbed Depreciation	0.42	1.66
<b>Total</b>	<b>6.72</b>	<b>6.30</b>

12 Other non current assets (Rs in lacs)

Particulars	31 October 2024	31 March 2024
Security Deposits		
-Security Deposits	10.41	9.31
IPO Expenses	12.71	-
<b>Total</b>	<b>23.12</b>	<b>9.31</b>

13 Inventories (Rs in lacs)

Particulars	31 October 2024	31 March 2024
Raw materials	22.31	9.34
Finished goods	142.95	113.48
<b>Total</b>	<b>165.26</b>	<b>122.82</b>

14 Trade receivables (Rs in lacs)

Particulars	31 October 2024	31 March 2024
Unsecured considered good		
-Trade receivables	93.97	98.93
<b>Total</b>	<b>93.97</b>	<b>98.93</b>



## 14.1 Trade Receivables ageing schedule as at 31 October 2024

(Rs in lacs)

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months- 1 year	1-2 years	2-3 years	More than 3 years	
Undisputed Trade receivables-considered good	93.97					93.97
Undisputed Trade Receivables-considered doubtful						-
Disputed Trade Receivables considered good						-
Disputed Trade Receivables considered doubtful						-
Sub total						93.97
Undue - considered good						-
<b>Total</b>						<b>93.97</b>

## 14.2 Trade Receivables ageing schedule as at 31 March 2024

(Rs in lacs)

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months- 1 year	1-2 years	2-3 years	More than 3 years	
Undisputed Trade receivables-considered good	98.93					98.93
Undisputed Trade Receivables-considered doubtful						-
Disputed Trade Receivables considered good						-
Disputed Trade Receivables considered doubtful						-
Sub total						98.93
Undue - considered good						-
<b>Total</b>						<b>98.93</b>

## 15 Cash and cash equivalents

(Rs in lacs)

Particulars	31 October 2024	31 March 2024
Cash on hand		
-Cash on hand	9.00	4.00
Balances with banks in current accounts		
-Others	1.56	0.17
Others		
-Others	-	1.67
<b>Total</b>	<b>10.56</b>	<b>5.84</b>

## 16 Short term loans and advances

(Rs in lacs)

Particulars	31 October 2024	31 March 2024
Others		
-Advance for Solar Plant	-	12.43
-Advance for Purchase of Goods	16.93	-
-Advance to Employees	6.03	-
<b>Total</b>	<b>23.26</b>	<b>12.43</b>

## 17 Other current assets

(Rs in lacs)

Particulars	31 October 2024	31 March 2024
Advance Tax	1.98	2.10
GST Receivable	3.23	-
Interest Accrued on DGVCL Deposit	-	0.42
TDS Receivable	-	1.16
<b>Total</b>	<b>5.21</b>	<b>3.68</b>

18 Revenue from operations (Rs in lacs)

Particulars	31 October 2024	31 March 2024
Sale of products		
-Sales-Domestic	330.16	528.82
-Sales-Exports	64.99	64.99
Other operating revenues		
-Job Work Income	31.52	53.72
<b>Total</b>	<b>426.67</b>	<b>647.53</b>

19 Other Income (Rs in lacs)

Particulars	31 October 2024	31 March 2024
Interest Income		
-Interest Income	0.00	0.47
-Interest on IT Refund	-	0.21
Net gain/loss on sale of investments		
-Loss on Sale of Mutual Funds	-	-
-Profit on Sale of Mutual Funds	-	-
Others		
-Appreciation on Mutual funds	-	0.01
-Other Income	8.70	0.44
-Rent Income	1.05	1.47
<b>Total</b>	<b>9.75</b>	<b>2.60</b>

20 Cost of Material Consumed (Rs in lacs)

Particulars	31 October 2024	31 March 2024
Raw Material Consumed		
Opening stock	9.34	1.05
Purchases	46.51	39.35
Less: Closing stock	22.31	9.34
<b>Total</b>	<b>33.55</b>	<b>31.06</b>
<b>Total</b>	<b>33.55</b>	<b>31.06</b>

21 Purchases of stock in trade (Rs in lacs)

Particulars	31 October 2024	31 March 2024
Purchases of stock in trade	121.23	217.10
<b>Total</b>	<b>121.23</b>	<b>217.10</b>

22 Change in inventories of work in progress and finished goods (Rs in lacs)

Particulars	31 October 2024	31 March 2024
Opening inventories		
Finished Goods	113.48	35.67
Less: Closing inventories		
Finished Goods	142.95	113.48
<b>Total</b>	<b>(29.47)</b>	<b>(77.81)</b>

23 Employee benefit expenses (Rs in lacs)

Particulars	31 October 2024	31 March 2024
Salaries and wages		
-Director's remuneration	5.48	6.88
-Salaries and wages	98.73	140.24
Contribution to provident and other funds		
-ESIC	0.41	0.63
-Provident Fund	3.53	5.06

Staff welfare expenses		
-Staff Welfare	0.66	3.22
Retirement Benefit Obligation	2.40	2.84
<b>Total</b>	<b>111.21</b>	<b>158.86</b>

24 Finance costs (Rs in lacs)

Particulars	31 October 2024	31 March 2024
Interest expense		
-Interest - Bank	5.68	10.05
-Interest on Loan	0.34	3.05
-Interest on Vehicle loan	0.59	1.22
Other borrowing costs		
-Bank Charges	1.15	0.65
<b>Total</b>	<b>7.75</b>	<b>14.97</b>

25 Depreciation and amortization expenses (Rs in lacs)

Particulars	31 October 2024	31 March 2024
Depreciation	21.18	40.36
<b>Total</b>	<b>21.18</b>	<b>40.36</b>

26 Other expenses (Rs in lacs)

Particulars	31 October 2024	31 March 2024
<b>Manufacturing Expenses:</b>		
Power & Fuel Expense	34.55	50.07
GIDC Expense	1.21	
Loading-Unloading Charges	2.31	
Packing Charges	17.81	9.09
Transportation Charges	7.40	
Other Manufacturing Expenses	2.76	6.86
<b>Payment to Auditors:</b>		
As auditor:		
-Audit Fee	0.00	0.35
<b>Administrative and Selling &amp; Distribution Expenses:</b>		
Accounting Charges		
Advertisement Expenditure	3.37	6.60
Business Promotion Expense	2.56	5.37
Conveyance & Travelling	2.41	0.00
Legal Fees	1.72	
Insurance Charges	1.15	0.40
Marketing and Other Expenses	21.05	31.73
Postage and Courier Expense	9.51	23.93
Printing & Stationery	1.10	
Rates & Taxes	0.00	1.23
Rent	2.24	2.99
Repairs & Maintenance	5.81	10.83
Security Service	1.04	
Other Administrative & Selling Expenses	6.77	51.14
<b>Total</b>	<b>124.79</b>	<b>200.59</b>

27 Tax Expenses (Rs in lacs)

Particulars	31 October 2024	31 March 2024
Current Tax		
-Current Year Tax	12.52	16.58
Deferred Tax		
-Deferred Tax Liability	(0.42)	(1.65)
<b>Total</b>	<b>12.10</b>	<b>14.93</b>

HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)  
(CIN: U24233GJ2007PLC049692)  
Notes forming part of the Financial Statements

28 Earning per share

Particulars	31 October 2024	31 March 2024
Profit attributable to equity shareholders (Rs in lacs)	34.08	50.07
Weighted average number of Equity Shares	3,136,000	1,960,000
Earnings per share basic (Rs)	1.09	2.55
Earnings per share diluted (Rs)	1.09	2.55
Face value per equity share (Rs)	10	10

29 Auditors' Remuneration

Particulars	31 October 2024	31 March 2024
Payments to auditor as - Auditor	-	0.35
<b>Total</b>	-	<b>0.35</b>

30 Micro and Small Enterprise

31 Related Party Disclosure

(i) List of Related Parties

Particulars	Relationship
Herrick Shah	Managing Director
Shrenik Shah	Whole Time Director
Mountbaton Shah	Relative of Director (CFO Till 13/06/2024)
HSDL Innovative Pvt Ltd	Associate Concern
Herrick Shah HUF	Director is Karta
V4U Healthcare Private Limited	Associate Concern
Adinath Medicine	Related Entity
Mahavir Medicine	Related Entity
Alkabon Shah	Relative of Director
Pallavi Shah	Director
Mountbaton Shah HUF	Relative of Director's HUF
Mitali Shrenik Shah	Chief Financial Officer (From 14/06/2024)
Komal Jain	Company Secretary

(ii) Related Party Transactions

Particulars	Relationship	31 October 2024	31 March 2024
Director Remuneration			
- Herrik Shah	Managing Director	2.63	2.58
- Shrenik Shah	Whole Time Director	2.10	2.00
- Mountbaton Shah	Relative of Director (CFO Till 13/06/2024)	0.75	2.30
- Mitali Shah	Chief Financial Officer (From 14/06/2024)	1.35	-
Rent Received			
- V4U Healthcare Private Limited	Associate Concern	1.05	1.35
Rent Paid			
- Mitali Shah	Chief Financial Officer (From 14/06/2024)	1.40	-
Purchase			
- HSDL Innovative Pvt Ltd	Associate Concern	43.60	49.64
Loan Accepted			
- Herrik Shah	Managing Director	19.50	5.00
- Shrenik Shah	Whole-Time Director	5.00	-
Continued to next page			

Related Party Transactions

Particulars	Relationship	31 October 2024	31 March 2024
Continued from previous page			
Loan Repaid			
- Herrik Shah	Managing Director	-	11.00
Jobwork Income			
- HSDL Innovative Pvt Ltd	Associate Concern	27.05	-
Sales			
- V4U Healthcare Private Limited	Associate Concern	8.01	10.95
- HSDL Innovative Pvt Ltd	Associate Concern	3.40	36.34
- Adinath Medicine	Related Entity	15.04	26.33
- Mahavir Medicine	Related Entity	5.06	9.06
Remuneration to Company Secretary			
- Komal Jain		1.40	0.60

(iii) Related Party Balances

Particulars	Relationship	31 October 2024	31 March 2024
Director's Remuneration Payable			
- Herrik Shah	Managing Director	0.34	0.71
Director Remuneration Payable			



- Shrenik Shah	Whole Time Director	0.27	0.54
- Moonibaton Shah	Relative of Director (CFD Till 13/06/2024)	-	0.54
Sundry Creditors			
- HSDI Innovative Pvt Ltd	Associate Concern	15.25	6.87
- V4U Healthcare Private Limited	Associate Concern	-	1.65
Borrowings			
- Harrik Shah	Managing Director	19.50	-
- Shrenik Moonibaton Shah	Whole-Time Director	5.00	-
Sundry Debtors			
- V4U Healthcare Private Limited	Associate Concern	2.16	-
- Admith Medicine	Related Entity	10.69	6.43
- Mahavir Medicine	Related Entity	2.15	2.48
Rent Receivable			
- V4U Healthcare Private Limited	Associate Concern	0.29	0.14
Company Secretary's Remuneration			
- Kamal Jain	Related Entity	0.70	0.20
Other Current Liability			
- Mitul Shah	Chief Financial Officer (From 14/06/2024)	0.23	-
Chief Financial Officer's Remuneration			
- Mitul Shah	Chief Financial Officer (From 14/06/2024)	0.68	-


As per our report of even date  
 For MGVS & Associates  
 Chartered Accountants  
 Firm's Registration No. 0140555W

CA MURASSIR M GODIL  
 PARTNER  
 Membership No. 164503

UDIN: 24164503BKDKST7871  
 Place: ANKLESHWAR  
 Date: 02 December 2024

For and on behalf of the Board of  
 HAMP BIO LIMITED (Formerly Known as Hamps Bio Private Limited)

  
 HERRIK SHAH  
 MANAGING DIRECTOR  
 01052316

  
 SHRENIK SHAH  
 WHOLE TIME DIRECTOR  
 00973690

## **HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)**

(CIN No – U24233GJ2007PLC049692)

2900/112, GIDC, NEAR ATUL LIMITED, ANKLESHWAR, GUJARAT – 393002

**SIGNIFICANT ACCOUNTING POLICIES & NOTES ON FINANCIAL STATEMENTS FOR THE YEAR ENDED 31<sup>ST</sup> OCTOBER, 2024**

### **Note 29**

#### **General information**

**HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)** (the 'Company') is a public limited company converted with effect from 12<sup>th</sup> July 2023 and is incorporated under the provisions of the Companies Act, 2013. The Company is engaged in the business of Trading and Manufacturing of Medicines and Processing and selling of Freeze dried products. The Registered Address of the Company is **Plot No 2900/112, GIDC Estate, Near Atul Limited, Ankleshwar, Bharuch, Gujarat – 393002** and books of account are maintained at **Shop No 120-121-122, 01st Floor, Royal Platinum, Palanpur Canal Road, Adajan, Surat, Gujarat, 395009.**

#### **Summary of significant accounting policies & Notes on Financial Statements for the year ended 31st October, 2024.**

##### **1. Basis Of Preparation Of Financial Statements**

- a. The financial statements have been prepared in accordance with the generally accepted accounting principles in India under the historical cost convention on accrual basis.
- b. The financial statements of the company have been prepared in accordance with generally accepted accounting principle in India (Indian GAAP). The financial statements have been prepared to comply in all material aspects with the accounting standards specified under Section 133 the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014 and the relevant provisions of the Companies Act, 2013. The financial statements have been prepared on an accrual basis and under the historical cost convention unless otherwise specified. The accounting policies adopted in the preparation of financial statements are consistent with those of previous year unless otherwise specified. The company has not changed any accounting policy and estimates.
- c. All assets and liabilities have been classified as current or non-current as per the Company's normal operating cycle and other criteria set out in the Schedule III to the Companies Act, 2013. Based on the nature of products and the time between the acquisition of assets for processing and their realization in cash and cash equivalents, the Company has ascertained its operating cycle as 12 months for the purpose of current – noncurrent classification of assets and liabilities.
- d. In the opinion of the Management, the Current Assets, Loans & Advances approximately are of the value stated if realized in the ordinary course of business.
- e. The company is maintaining the books of accounts on mercantile system by following exclusive method on regular basis. Thus, there is a deviation from the provisions of section 145A for the valuation of purchase and sales of goods. i.e. GST is not included in the total amount of purchases and sales as recorded in the profit and loss account. However, by following the exclusive method, there is no effect on the net profit i.e. the method adopted by the company is revenue neutral.

## **HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)**

(CIN No – U24233GJ2007PLC049692)

2900/112, GIDC, NEAR ATUL LIMITED, ANKLESHWAR, GUJARAT – 393002

### **2. Use Of Estimates**

The preparation of financial statements requires management to make judgments, estimates and assumptions, that affect the application of accounting policies and the reported amounts of assets and liabilities and disclosures of contingent liabilities at the date of these financial statements and the reported amounts of revenues and expenses for the years presented. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised and future periods affected.

### **3. Revenue Recognition**

The Company recognizes revenue when the amount of revenue can be reliably measured and it is probable that the collectability of the related receivables is reasonably assured. The amount recognized as income is exclusive of GST and net of trade discounts.

#### **a. Sales**

Sales whether domestic and Export sales are recognized when all the significant risks and rewards of ownership of the goods have been passed to the buyer, on dispatch from the point of sale, consequent to property in goods being transferred.

#### **b. Interest income**

Interest income is recognized on a time proportion basis taking into account the amount outstanding and the applicable interest rate.

Revenue from the sale of goods is recognized in the statement of profit and loss account when the ownership of the goods is transferred for the price and all significant risk and rewards of ownership have been transferred to the buyer and the company retains no effective control of the goods when there exists no significant uncertainty regarding the amount of consideration that will be derived from the sale of goods. Sales and purchases are recorded by exclusive method on regular basis. Thus there is deviation from the provisions of section 145A for valuation of purchase and sales of goods i.e. GST is not included in the total amount of purchases and sales as recorded in the Profit and loss account. However, by following the exclusive method, there is no effect on the Net profit i.e. the method adopted by the company is revenue neutral.



## **HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)**

(CIN No – U24233GJ2007PLC049692)

2900/112, GIDC, NEAR ATUL LIMITED, ANKLESHWAR, GUJARAT – 393002

#### **4. Property, Plant and Equipments & Depreciation:**

##### **a. Property, Plant and Equipments –Tangibles and intangibles**

Property, Plant and Equipment's are stated at cost of acquisition net of recoverable taxes and includes amount added on revaluation, less accumulated depreciation and impairment loss, if any. The cost of Property, Plant and Equipment's includes cost of acquisition plus any freight, taxes, duties and other incidental expenses that are directly attributable to bring the assets to their present location and condition for their intended use. Borrowing costs, if any, directly attributable to the qualifying assets are capitalized as part of the assets.

When spares, if any are used only in connection with the item of tangible assets and their use is expected to be irregular, then the cost of these spares is capitalized in the cost of the assets. Subsequent expenditure relating to the Property, Plant and equipment is capitalized only when it is probable that future economic benefits associated with these will flow to the company and the cost of the item can be measured reliably. No assets have been revalued during the year.

The Company does not have any intangible assets.

##### **b. Depreciation and Amortization**

Depreciation on tangible assets is provided on the written down value method over the useful lives of assets prescribed under Part A of Schedule II to the Companies Act, 2013, in order to reflect the actual usage of the assets. Depreciation for assets purchased / sold during a period is proportionately charged. The useful lives for the Property, Plant and Equipment's as per Schedule II of the Companies Act are as follows:

<b>Name of Property, Plant and Equipments</b>	<b>Useful Life</b>
Factory Buildings	30 years
Building other than factory building	60 years
Plant and machinery	15 years
Electric installation	10 Years
Computer	3 Years
Office equipment	5 years
Air Conditioner	10 Years
Furniture and fixtures	10 years
Vehicles	10 years
Solar System	15 Years



## **HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)**

(CIN No – U24233GJ2007PLC049692)

2900/112, GIDC, NEAR ATUL LIMITED, ANKLESHWAR, GUJARAT – 393002

Depreciation and amortization methods, useful lives and residual values are reviewed periodically and there is no change in any of the above at financial year end.

### **5. Investments**

Investments, which are readily realizable and intended to be held for not more than one year from the date on which such investments are made, are classified as current investments. All other investments are classified as long-term investments.

On initial recognition, all investments are measured at cost. The cost comprises purchase price and directly attributable acquisition charges such as brokerage, fees and duties. Long-term investments are carried at cost. However, provision for diminution in value of investments is made to recognize a decline other than temporary in the value of investment.

Current investments are carried in the financial statement at cost of acquisition on an individual investment basis.

On disposal of an investment, the difference between its carrying amount and net disposal proceeds is charged or credited to the statement of profit and loss.

Provision for diminution in the value of Long-Term Investments is made only if; such decline in the opinion of the management is other than temporary.

### **6. Inventories**

Inventory consists of Raw material, Finished Goods and Stock In Trade. Inventory is valued at cost or market value whichever is lower.

#### ***Cost***

Cost of Inventories comprises of cost of Purchase, cost of conversion and other cost including manufacturing overheads incurred in bringing them to their respective present location & condition. Cost is determined by following FIFO Method.

The company has valued its closing stock by exclusive method i.e. excluding of GST.

### **7. Retirement Benefits:**

Expenses & liabilities in respect of employee benefits are recorded in accordance with the Revised Accounting Standard (AS)-15 –Employee Benefits (revised 2005)

## **HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)**

(CIN No – U24233GJ2007PLC049692)

2900/112, GIDC, NEAR ATUL LIMITED, ANKLESHWAR, GUJARAT – 393002

a. ***Short term employee benefits***

All employee benefits payable wholly within twelve months of rendering the service are classified as short-term employee benefits. The undiscounted amount of short-term employee benefits expected to be paid in exchange for the services rendered by employees is charged to the Statement of profit and loss in the period in which such services are rendered.

b. ***Other long-term employee benefits***

The company has not provided any leave encashment / salary to the employees as the employees fully utilizes their leaves during the year.

8. **Taxes On Income**

a. ***Current Tax***

Provision for current tax is recognized in accordance with the provisions of the Income-tax Act, 1961 and is made based on the tax liability after taking credit for tax allowances and exemptions.

b. ***Minimum Alternative Tax Credit***

Minimum Alternative Tax ('MAT') credit is recognized only to the extent there is convincing evidence that the Company will pay normal income tax in excess of MAT during the specified period. MAT credit entitlement is reviewed as at each Balance sheet date and written down to the extent there is no longer convincing evidence that the Company will pay normal income tax during the specified period.

c. ***Deferred Taxation***

Deferred Tax is recognized, subject to the consideration of prudence and virtual certainty for deferred tax assets, on timing difference between taxable income and accounting income that originate in one year and are capable of reversal income and more subsequent years. Deferred Tax assets and liabilities are measured using the tax rate and tax laws that have been enacted or substantially enacted by the balance sheet date.

Deferred Tax Assets includes unabsorbed tax depreciation/carried forward losses, which is recognized to the extent it can be realized against the reversal of deferred tax liability on account of depreciation. In the current year no addition to Deferred Tax Assets is being made as there is no reasonable certainty in earning taxable profit.

## **HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)**

(CIN No – U24233GJ2007PLC049692)

2900/112, GIDC, NEAR ATUL LIMITED, ANKLESHWAR, GUJARAT – 393002

(Rs in lakhs)

<i>Particulars</i>	<i>For the year ended 31<sup>st</sup> October 2024</i>	<i>For the year ended 31<sup>st</sup> March 2024</i>
<b>Opening Balance</b>	<b>(6.30)</b>	<b>(4.64)</b>
i. Depreciation	0.00	0.00
i. Depreciation	(0.42)	(1.66)
ii. Gratuity	0.00	0.00
iii. Loss on Income tax	0.00	0.00
iv. Other Disallowance (which will be allowed in future)	0.00	0.00
<b>Total Deferred Tax Liability / (Asset)</b>	<b>(6.72)</b>	<b>(6.30)</b>

### **9. Investments**

Investments which are readily realizable and intended to be held for not more than one year from the date on which such investments are made, are classified as Current investments. All other investments are classified as long term investments.

Current Investments are carried in the Financial Statements at lower of cost or fair value determined on an individual investment basis. Long Term Investments are stated at cost of acquisition.

Provision for diminution in the value of Long-Term Investments is made only if; such decline in the opinion of the management is other than temporary.

### **10. Borrowing Cost**

Borrowing costs that are attributable to the acquisition or construction of qualifying assets are capitalized as part of the cost of such assets. A qualifying asset is one that necessarily takes substantial period of time to get ready for intended use.

All other borrowing costs are charged to Profit and Loss account.

During the year under reporting, the company has not borrowed any funds for acquisition of any qualifying assets and not purchased any Property, Plant and Equipment and hence there is no borrowing cost which requires capitalization.

Inventories do not require the period of 12 months or more to bring them in a saleable condition and hence there is no question of capitalization of borrowing cost arises.



## **HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)**

(CIN No – U24233GJ2007PLC049692)

2900/112, GIDC, NEAR ATUL LIMITED, ANKLESHWAR, GUJARAT – 393002

### **11. Cash And Cash Equivalents**

Cash and cash equivalents in the balance sheet comprise cash at banks; cash in hand, other short term deposits with original maturities of three months or less which are subject to an insignificant risk of changes in value.

### **12. Cash Flows**

Cash Flows are reported using the indirect method, where by net profit before tax is adjusted for the effects of transactions of a non cash nature, any deferrals or accruals of past or future operating cash receipts or payments and item of income or expenses associated with investing or financing cash flows. The cash flows from operating, investing and financing activities are segregated. Being a Level II Enterprise as defined by ICAI in an announcement issued 'Criteria for classification of Entities and applicability of accounting standards', the company is exempted from compliance with AS 3 Cash Flow Statements.

### **13. Segment Reporting**

Based on guiding principles given in the Accounting standard on 'Segment Reporting' (AS-17), the primary business segment of the Company is manufacturing & trading of medicines and Secondary business segment of the company is manufacturing of Freeze dried products, etc. The details of the same is as follows:

(Rs in lacs)

<b>Year ended 31<sup>st</sup> October, 2024</b>	<b>Medicine Products (Rs.)</b>	<b>Freeze dried Products (Rs.)</b>	<b>Total (Rs.)</b>
Segment Revenue	211.64	215.03	<b>426.67</b>
Segment Results	16.66	16.93	<b>33.58</b>
Segment Assets	155.74	158.23	<b>313.97</b>

### **14. Comparatives**

Comparative financial information is presented in accordance with the "Corresponding Figure" financial reporting framework set out in "Standard of Auditing 710" on Comparatives. Accordingly, amounts and other disclosures for the preceding year are included as an integral part of the current year financial statements, and are to be read in relation to the amounts and other disclosures relating to the current year.



## **HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)**

(CIN No – U24233GJ2007PLC049692)

2900/112, GIDC, NEAR ATUL LIMITED, ANKLESHWAR, GUJARAT – 393002

### **15. Earnings Per Share (EPS)**

EPS is calculated by dividing the profit attributable to the equity shareholders by the weighted average number of equity shares outstanding during the year. Numbers used for calculating basic & diluted earnings per equity shares are as stated below:

#### **a. Calculation of Weighted Average No. of Equity Shares**

<i>Particulars</i>	<i>For the year ended 31st October, 2024</i>	<i>For the year ended 31st March, 2024</i>
Number of Equity Shares	31,36,000	19,60,000
<b>Total Weighted Average No. of Equity Shares (Basic)</b>	<b>31,36,000</b>	<b>19,60,000</b>
Add : Dilution Effect on account of Share Application Money pending allotment * Time Effect		-
<b>Total Weighted Average No. of Equity Shares (Diluted)</b>	<b>31,36,000</b>	<b>19,60,000</b>

#### **b. Basic EPS**

*(Rs in lacs)*

<i>Particulars</i>	<i>For the year ended 31st October, 2024</i>	<i>For the year ended 31st March, 2024</i>
Profit after Taxation as per statement of Profit & Loss	34.08	50.06
Weighted average no. of Equity Shares outstanding	31,36,000	19,60,000
<b>Basic Earnings per share (Face Value Rs. 10)</b>	<b>1.09</b>	<b>2.55</b>

#### **c. Diluted EPS**

*(Rs in lacs)*

<i>Particulars</i>	<i>For the year ended 31st October, 2024</i>	<i>For the year ended 31st March, 2024</i>
Profit after Taxation as per statement of Profit & Loss	34.08	50.06
Weighted average no. of Equity Shares outstanding	31,36,000	19,60,000
<b>Diluted Earnings per share (Face Value Rs. 10)</b>	<b>1.09</b>	<b>2.55</b>

## **HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)**

(CIN No – U24233GJ2007PLC049692)

2900/112, GIDC, NEAR ATUL LIMITED, ANKLESHWAR, GUJARAT – 393002

### **16. Related Party Disclosures**

#### ***a. Name of the related party and the description of relationship-***

<b>Particulars</b>	<b>Name</b>
Key Managerial Personnel (KMPs)	Mr. Herrik Shah, Managing Director
	Mr. Shrenikkumar Shah, Whole Time Director
	Mrs. Komal Jain, Company Secretary
	Mr. Mitali Shrenik Shah, Chief Financial officer (From 14/06/2024)
Associate Concern	V4U Healthcare Private Limited
	HSDL Innovative Private Limited
Related Entities	M/s. Adinath Medicine, M/s. Mahavir Medicine
Relatives of KMPs	Mrs. Alkaben Shah, Mrs. Pallavi Shah, Herrik Shah HUF, Mountbaton Shah HUF, Mountbaton Shah (CFO till 13/06/2024)

#### ***b. Enterprises over which Key Management Personnel have control/Substantial Interest/Significant Influence –***

<b>Nature of Relation</b>	<b>Name of Director</b>	<b>Enterprise Name</b>
<i>As a Director</i>	Mr. Shrenikkumar Shah	V4U Healthcare Private Limited
<i>As a Director</i>	Mr. Herrik Shah	V4U Healthcare Private Limited
<i>As a Director</i>	Mr. Herrik Shah	HSDL Innovative Private Limited
<i>As a Proprietor</i>	Mr. Herrik Shah	M/s. Mahavir Medicine
<i>As a Karta of HUF</i>	Mr. Herrik Shah	M/s. Adinath Medicine

#### ***c. Transactions With Related Parties For The Year Ended 31 October, 2024 are As Follows:-***

<b>Name</b>	<b>Nature of Transaction</b>	<b>Amount (Rs. in lacs)</b>	<b>Amount (Rs. in lacs)</b>
		<b>31<sup>st</sup> October 2024</b>	<b>31st March 2024</b>
Mr. Herrik Shah	Director Remuneration	2.63	2.58
	Loan Accepted	19.50	5.00
	Loan Repaid	-	11.00
Mr. Shrenikkumar Shah	Director Remuneration	2.10	2.00
	Loan Accepted	5.00	-
Mr. Mountbaton Shah	Director Remuneration	0.75	2.30

## **HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)**

(CIN No – U24233GJ2007PLC049692)

2900/112, GIDC, NEAR ATUL LIMITED, ANKLESHWAR, GUJARAT – 393002

Mrs. Mitali Shah	Director's remuneration	1.35	-
	Rent	1.40	
M/s. V4U Healthcare Private Limited	Sales	8.01	10.95
	Rent	1.05	1.35
M/s. HSDL Innovative Private Limited	Purchase	43.60	49.64
	Sales	3.40	36.34
	Jobwork Income	27.05	-
M/s. Adinath Medicine	Sales	15.04	26.33
M/s. Mahavir Medicine	Sales	5.06	9.06
Mrs. Komal Jain	Remuneration	1.40	0.60

### **17. Auditor's Remuneration**

It is included Net of applicable Taxes in P & L, under the head Other Expenses – Audit Fees as follows:

<i>Particulars</i>	<i>For the year ended 31st October, 2024</i>	<i>For the year ended 31st March, 2024</i>
		<i>(in Lacs)</i>
Audit Fees	-	0.35
<b><u>TOTAL</u></b>	-	<b>0.35</b>

### **18. Foreign currency translation**

#### ***a. Initial Recognition***

Foreign currency transactions are recorded in the reporting currency, by applying to the foreign currency amount the exchange rate between the reporting currency and the foreign currency at the date of the transaction.

#### ***b. Conversion***

Foreign currency monetary items are retranslated using the exchange rate prevailing at the reporting date.

#### ***c. Exchange differences***



## **HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)**

(CIN No – U24233GJ2007PLC049692)

2900/112, GIDC, NEAR ATUL LIMITED, ANKLESHWAR, GUJARAT – 393002

The Company accounts for exchange differences arising on translation/settlement of foreign currency monetary items as below:

Exchange differences which arise on reporting the enterprise's long-term foreign currency monetary items are recognized as income or as an expense during the year under consideration. All other exchange differences are recognized as income or as expenses in the period in which they arise.

### **d. Details Foreign Currency Transactions**

<i>Particulars</i>	<i>For the year ended 31st October, 2024</i>	<i>For the year ended 31st March, 2024</i>
		<i>(In Lacs)</i>
Earnings in Foreign Currency Export of Goods on FOB Basis	64.99	64.99
Value of Import on CIF Basis	64.99	64.99

### **19. Provisions & Contingent Liabilities**

Provisions are reviewed at each Balance sheet date and adjusted to reflect the current best estimate. If it is no longer probable that an outflow of resources would be required to settle the obligation, the provision is reversed.

Contingent Liabilities are not recognized but are disclosed in the notes. Contingent Assets are neither recognized nor disclosed in the financial statements.

- 20.** The Company has received intimation from suppliers regarding their status under the Micro, Small and Medium Enterprises Development Act, 2006 and hence disclosures, relating to amounts unpaid as at the yearend together with interest paid/payable as required under the said Act have been given below. The Company has identified the amount due to Micro, Small and Medium Enterprises under The Micro, Small and Medium Enterprises Development Act,2006 (MSMED Act) as at 31st March, 2024 is as follows:

## **HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)**

(CIN No – U24233GJ2007PLC049692)

2900/112, GIDC, NEAR ATUL LIMITED, ANKLESHWAR, GUJARAT – 393002

Sr. No.	Particulars	Financial Year 2024-25 (Till Oct'24)	Financial Year 2023-24
i)	The principal amount and the interest due thereon remaining unpaid to any supplier as at 31st March.		
	Principal Amount	7.47	19.51
	Interest	-	-
ii)	The amount of interest paid by the Company along with the amounts of the payment made to the supplier beyond the appointed day for the year ending 31st March.	-	-
iii)	The amount of interest due and payable for the period of delay in making payment (beyond the appointed day during the year)	-	-
iv)	The amount of interest accrued and remaining unpaid for the year ending 31st March.	-	-
v)	The amount of further interest remaining due and payable for the earlier years.	-	-

**Note:** The information has been given in respect of such suppliers to the extent they could be identified as "Micro, Small and Medium" enterprises on the basis of information available with the Company.

21. During the year under consideration, there is no amount in respect of sale of goods which is not recognized as revenue due to lack of reasonable certainty of its ultimate collection.
22. The Company has not dealt in any foreign trade or transactions involving foreign exchange during the year under reporting. Therefore, the gain/loss on foreign exchange transactions is not recognized in the financial statements for the period under reporting.
23. The Company has not received any duty drawback during the year under reporting on revenue account and accounting policy of the same has been mentioned above.
24. The firm has not dealt in any trading transactions of securities and hence no securities are held as stock in trade.
25. No proceedings have been initiated or are pending against the Company for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and Rules made there under.
26. No loans or advances in the nature of loans are granted to promoters, Directors, Key Managerial Personnel and the related parties (as defined under the Companies Act, 2013) either severally or jointly with any other person.
27. Balances in the accounts of Trade Receivables, Loans and Advances, Trade Payables and Other Current Liabilities are subject to confirmation / reconciliation, if any.



**HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)**

(CIN No – U24233GJ2007PLC049692)

2900/112, GIDC, NEAR ATUL LIMITED, ANKLESHWAR, GUJARAT – 393002

28. In the opinion of the Management, current assets, loans, advances and deposits are approximately of the value stated, if realised in the ordinary course of business and are subject to confirmation.
29. All the expenses pertaining to the period ending on 31st October, 2024 have been accounted on accrual basis.
30. Previous year's figures have been regrouped and/or reclassified wherever necessary to make them comparable with current year figures.
31. The Company has not traded or invested in Crypto currency or Virtual Currency during the financial year.
32. The Company is not declared wilful defaulter by any bank or financial institution or other lenders.

In Terms Of Our Attached Report of Even Date  
For MGVS AND ASSOCIATES  
Chartered Accountants



CA MUBASSIR M GODIL  
(Partner)

M. No. : 164503  
FRN: 0140555W  
Place: Ankleshwar  
Date: 02/12/2024  
UDIN: 24164503BKDKST7871

For HAMPS BIO LIMITED  
(Formerly known as Hamps Bio Private Limited)

FOR, HAMPS BIO LIMITED

DIRECTOR

HERRIK SHAH  
(MANAGING  
DIRECTOR)  
(DIN: 01052316)

FOR, HAMPS BIO LIMITED

DIRECTOR

SHRENIK SHAH  
(WHOLE TIME DIRECTOR)  
(DIN: 0097369)